Objective To summarize and investigate the comparative efficacy and safety of targeted
disease-modifying antirheumatic drugs (DMARDs) for active psoriatic arthritis (PsA). Methods …

The use of immunosuppressive drugs is a potential risk factor for infectious disease, including
COVID-19 illness. 1 For instance, although dexamethasone improves survival among …

Importance Biological therapies have revolutionized inflammatory bowel disease management,
but many patients do not respond to biological monotherapy. Identification of likely …

Background Safety of anti-tumour necrosis factor-α (TNFα) therapy in people with a history
of cancer and with an immune-mediated disease is unknown. We aimed to assess the risk of …

Although low-dose and short-term glucocorticoid use is extremely common and effective in
RA management, increasing evidence of toxicity has led experts to begin recommending that …

… Beth I. Wallacea,b,c, Laura Cooneya and David A. Foxa … New molecular targets in the
treatment of rheumatoid arthritis Wallace et al. … New molecular targets in the treatment of …

Background Although patients with rheumatic and musculoskeletal diseases (RMDs) are at
increased risk for adverse outcomes of COVID-19 illness compared to healthy controls, they …

Objectives Over one-third of patients with RA exhibit evidence of fibromyalgianess, which is
associated with higher rates of disability and inadequate responsiveness to RA treatment. …

Background Antenatal corticosteroids are considered the standard of care for pregnant women
at risk for preterm birth, but studies examining their potential risks are scarce. We aimed …

Objective Glucocorticoids are common in RA management despite an unfavorable,
exposure-dependent risk profile impacted by patient and provider-level factors. Existing work …